Nemifitide diTFA

Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action[1]. Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF)[2]. Nemifitide diTFA can cross the blood-brain barrier[3].

Signaling Pathways >> Others >> Others

Research Areas >> Neurological Disease

Nemifitide diTFA (INN 00835 diTFA) and its active metabolite (M1) bind at micromolar concentrations to several receptors including the 5-HT2A, 5-HT2C, melanocortin MC4, MC5 and bombesin[3].

Nemifitide diTFA (INN 00835 diTFA; 0.3 mg/kg; IP; daily; for 14 days) significantly increases swimming in the FSL rats after just 5 days of treatment and has long-lasting effect[2]. Nemifitide diTFA (0.0125-15.0 mg/kg) significantly increases swimming in the FSL rats at both low (0.025-0.3 mg/kg) and high (3.0-15.0 mg/kg) doses but not at intermediate (0.4-2.4 mg/kg) doses[2]. Animal Model: Male Flinders Sensitive Line (FSL) rat weighing 280-320 g[2] Dosage: 0.3 mg/kg Administration: IP; daily; for 14 days Result: Significantly increased swimming in the FSL rats after just 5 days of treatment and had long-lasting effect.

[1]. Kelly JP, et al. The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients. J Affect Disord. 1999 Oct;55(2-3):231-5.

[2]. Overstreet DH, et al. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology (Berl). 2004 Sep;175(3):303-9.

[3]. Montgomery SA, et al. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressivedisorder. Int J Neuropsychopharmacol. 2006 Oct;9(5):517-28.